Merkel cell carcinoma: Clinical practice guidelines in oncology™

Stanley J. Miller; Murad Alam; James Andersen; Daniel Berg; Christopher K. Bichakjian; Glen Bowen; Richard T. Cheney; Frank Glass; Roy C. Grekin; James M. Grichnik; Timothy M. Johnson; Anne Kessinger; Nancy Y. Lee; Stuart Lessin; Daniel D. Lydiatt; Lawrence W. Margolis; Kishwer S. Nehal; Paul Nghiem; Allan R. Oseroff; E. William Rosenberg; Ashok R. Shaha; Ronald J. Siegle

doi:10.6004/jnccn.2006.0060

Merkel cell carcinoma: Clinical practice guidelines in oncology™

Stanley J. Miller^*, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, Frank Glass, Roy C. Grekin, James M. Grichnik, Timothy M. Johnson, Anne Kessinger, Nancy Y. Lee, Stuart Lessin, Daniel D. Lydiatt, Lawrence W. Margolis, Kishwer S. Nehal, Paul Nghiem, Allan R. Oseroff, E. William RosenbergAshok R. Shaha, Ronald J. Siegle

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.

Original language	English (US)
Pages (from-to)	704-712
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	4
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2006.0060
State	Published - Aug 2006

Keywords

Merkel cell carcinoma
NCCN Clinical Practice Guidelines
Neuroendocrine sarcoma
Nonmelanoma skin cancer
Sentinel lymph node biopsy

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2006.0060

Cite this

Miller, S. J., Alam, M., Andersen, J., Berg, D., Bichakjian, C. K., Bowen, G., Cheney, R. T., Glass, F., Grekin, R. C., Grichnik, J. M., Johnson, T. M., Kessinger, A., Lee, N. Y., Lessin, S., Lydiatt, D. D., Margolis, L. W., Nehal, K. S., Nghiem, P., Oseroff, A. R., ... Siegle, R. J. (2006). Merkel cell carcinoma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(7), 704-712. https://doi.org/10.6004/jnccn.2006.0060

@article{4176091ff78d4263b5ee9c69c033998a,

title = "Merkel cell carcinoma: Clinical practice guidelines in oncology{\texttrademark}",

abstract = "Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.",

keywords = "Merkel cell carcinoma, NCCN Clinical Practice Guidelines, Neuroendocrine sarcoma, Nonmelanoma skin cancer, Sentinel lymph node biopsy",

author = "Miller, {Stanley J.} and Murad Alam and James Andersen and Daniel Berg and Bichakjian, {Christopher K.} and Glen Bowen and Cheney, {Richard T.} and Frank Glass and Grekin, {Roy C.} and Grichnik, {James M.} and Johnson, {Timothy M.} and Anne Kessinger and Lee, {Nancy Y.} and Stuart Lessin and Lydiatt, {Daniel D.} and Margolis, {Lawrence W.} and Nehal, {Kishwer S.} and Paul Nghiem and Oseroff, {Allan R.} and Rosenberg, {E. William} and Shaha, {Ashok R.} and Siegle, {Ronald J.}",

year = "2006",

month = aug,

doi = "10.6004/jnccn.2006.0060",

language = "English (US)",

volume = "4",

pages = "704--712",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

Miller, SJ, Alam, M, Andersen, J, Berg, D, Bichakjian, CK, Bowen, G, Cheney, RT, Glass, F, Grekin, RC, Grichnik, JM, Johnson, TM, Kessinger, A, Lee, NY, Lessin, S, Lydiatt, DD, Margolis, LW, Nehal, KS, Nghiem, P, Oseroff, AR, Rosenberg, EW, Shaha, AR & Siegle, RJ 2006, 'Merkel cell carcinoma: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 7, pp. 704-712. https://doi.org/10.6004/jnccn.2006.0060

TY - JOUR

T1 - Merkel cell carcinoma

T2 - Clinical practice guidelines in oncology™

AU - Miller, Stanley J.

AU - Alam, Murad

AU - Andersen, James

AU - Berg, Daniel

AU - Bichakjian, Christopher K.

AU - Bowen, Glen

AU - Cheney, Richard T.

AU - Glass, Frank

AU - Grekin, Roy C.

AU - Grichnik, James M.

AU - Johnson, Timothy M.

AU - Kessinger, Anne

AU - Lee, Nancy Y.

AU - Lessin, Stuart

AU - Lydiatt, Daniel D.

AU - Margolis, Lawrence W.

AU - Nehal, Kishwer S.

AU - Nghiem, Paul

AU - Oseroff, Allan R.

AU - Rosenberg, E. William

AU - Shaha, Ashok R.

AU - Siegle, Ronald J.

PY - 2006/8

Y1 - 2006/8

N2 - Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.

AB - Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.

KW - Merkel cell carcinoma

KW - NCCN Clinical Practice Guidelines

KW - Neuroendocrine sarcoma

KW - Nonmelanoma skin cancer

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=33747697824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747697824&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0060

DO - 10.6004/jnccn.2006.0060

M3 - Review article

C2 - 16884672

AN - SCOPUS:33747697824

SN - 1540-1405

VL - 4

SP - 704

EP - 712

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Merkel cell carcinoma: Clinical practice guidelines in oncology™

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this